Ribavirin Treatment Effects on Breast Cancers Overexpressing eIF4E, a Biomarker with Prognostic Specificity for Luminal B-Type Breast Cancer

Filippa Pettersson1, Christina Yau3, Monica C. Dobocan1, Biljana Culjkovic-Kraljacic2, Héléne Retrouvay1, Rachel Puckett3, Ludmila M. Flores4, Ian E. Krop5, Caroline Rousseau1, Eftihia Cocolakis1, Katherine L. B. Borden6, Christopher C. Benz5, and Wilson H. Miller, Jr.1

Abstract

**Purpose:** We have evaluated the eukaryotic translation initiation factor 4E (eIF4E) as a potential biomarker and therapeutic target in breast cancer. eIF4E facilitates nuclear export and translation of specific, growth-stimulatory mRNAs and is frequently overexpressed in cancer.

**Experimental Design:** Breast cancer cells were treated with ribavirin, an inhibitor of eIF4E, and effects on cell proliferation and on known mRNA targets of eIF4E were determined. eIF4E expression was assessed, at the mRNA and protein level, in breast cancer cell lines and in skin biopsies from patients with metastatic disease. Additionally, pooled microarray data from 621 adjuvant untreated, node-negative breast cancers were analyzed for eIF4E expression levels and correlation with distant metastasis–free survival (DMFS), overall and within each intrinsic breast cancer subtype.

**Results:** At clinically relevant concentrations, ribavirin reduced cell proliferation and suppressed clonogen potential, correlating with reduced mRNA export and protein expression of important eIF4E targets. This effect was suppressed by knockdown of eIF4E. Although eIF4E expression is elevated in all breast cancer cell lines, variability in ribavirin responsiveness was observed, indicating that other factors contribute to an eIF4E-dependent phenotype. Assessment of the prognostic value of high eIF4E mRNA in patient tumors found that significant discrimination between good and poor outcome groups was observed only in luminal B cases, suggesting that a specific molecular profile may predict response to eIF4E-targeted therapy.

**Conclusions:** Inhibition of eIF4E is a potential breast cancer therapeutic strategy that may be especially promising against specific molecular subtypes and in metastatic as well as primary tumors. *Clin Cancer Res; 17(9); 2874–84. ©2011 AACR.*

Introduction

Eukaryotic translation initiation factor 4E (eIF4E) is an oncogene that is overexpressed in a wide range of cancers (1). It has been reported that greater than 50% of breast cancers express elevated levels of the eIF4E protein, and that high levels correlate with increased angiogenesis, clinical progression, and poor prognosis (2–4). The eIF4E protein is present both in the nucleus, where it acts to facilitate export of a subset of specific, growth promoting mRNAs (5), and in the cytoplasm, where it recruits mRNAs with highly structured 5′UTRs to the ribosome for initiation of translation (6, 7). This way, eIF4E mediates a tight regulation of expression of many proteins that are critical to cell division, cell growth and angiogenesis, including cyclin D1, survivin, c-myc, ornithine decarboxylase (ODC), and vascular endothelial growth factor (VEGF; ref. 6). eIF4E activity is modulated by a large number of proteins including the eIF4E binding proteins (4EBP), promyelocyte leukemia protein (PML), maskin, Cup, and various homeodomain proteins (8–10). Notably, the mammalian target of rapamycin (mTOR) prevents sequestration of eIF4E by 4EBP through phosphorylation of 4EBP, thereby activating eIF4E (11). mTOR is a validated clinical target, as evidenced by the clinical approval of selective TOR complex 1 (TORC1) inhibitors (rapalogs; ref. 12) which, unfortunately, have shown only limited clinical activity in phase II breast cancer trials (13, 14). Some clinical limitations of the rapalogs include (i) lack of validated tumor marker(s) predictive of responsiveness, (ii) lack of effect on the TORC2 complex, which activates AKT, (iii) release of p70S6 kinase–mediated negative feedback, resulting in secondary tumor activation.
Translational Relevance

Breast cancer is a heterogeneous disease. Some subtypes, most notably the hormone-dependent and HER2-positive tumors, can be effectively treated with targeted therapies. For other subtypes, in particular luminal B and basal-like tumors, there is still a great need for new prognostic and predictive biomarkers that can be therapeutically targeted. We have evaluated the eukaryotic translation initiation factor 4E (eIF4E) as a potential breast cancer biomarker and therapeutic target. We show that an eIF4E-inhibitor, ribavirin, has growth inhibitory activity against several breast cancer cell lines with elevated eIF4E, but not against normal mammary epithelial cells. We also show that eIF4E is overexpressed in breast cancer cell lines, in early stage primary breast tumors, and in breast cancer metastases. Importantly, we find that elevated eIF4E mRNA is an indicator of poor prognosis specifically in luminal B breast cancers, suggesting that this aggressive breast cancer subtype may be most responsive to eIF4E-targeted therapeutics.

Not all breast cancers overexpress eIF4E, suggesting that the efficacy of ribavirin in targeting eIF4E is likely to be specific to some tumor subtypes (24). As breast cancer is a highly heterogeneous disease with respect to both biological and clinical behavior, it is imperative to understand the interplay between intrinsic breast cancer characteristics, eIF4E expression levels, and sensitivity to an eIF4E-targeted therapeutic such as ribavirin. Intrinsic breast cancer subtypes are now commonly defined by gene expression profiling as luminal A, luminal B, basal-like, HER2-overexpressing, and normal breast-like tumors (25–27). Luminal breast cancers are predominantly steroid receptor (ER, PR) positive, whereas basal-like breast cancers are “triple-negative” tumors that express neither ER, PR nor HER2 receptors (27). This molecular subtyping of breast cancers has been shown to add prognostic information to standard clinical parameters and to predict likelihood of treatment response (27, 28). In particular, among all ER and/or PR overexpressing breast cancers, luminal A tumors are associated with high proliferation rates, worse outcome and resistance to endocrine therapy, whereas luminal B tumors are associated with high proliferation rates, worse outcome and resistance to endocrine therapy (27, 28). Although targeted therapies exist and are quite effective against HER2-positive and luminal A breast cancers, for other subtypes like luminal B and basal-like breast cancers there is still a great need for targeted therapeutics as well as companion prognostic and predictive biomarkers.

In the current study, we have evaluated eIF4E as a potential biomarker and therapeutic target in breast cancer. We assessed the ability of clinically relevant concentrations of ribavirin to suppress growth of breast cancer cell lines that overexpress eIF4E, and correlated this with the ability of ribavirin to suppress downstream eIF4E targets including cyclin D1, NBS1, VEGF, and phospho-AKT. Notably, we showed that ribavirin suppresses proliferation of breast cancer cell in an eIF4E-dependent manner. We further interrogated pooled microarray data from 621 adjuvant naive, node-negative breast cancer cases with respect to their intrinsic molecular subtypes, eIF4E transcript levels and metastatic outcome (DMFS). From this analysis, we observed that while eIF4E overexpression commonly occurs in different breast cancer subtypes, its prognostic value is restricted to luminal B cases.

Materials and Methods

Cells and reagents

Cells were maintained in Dulbecco’s modified Eagle’s medium (DMEM; MCF-7, MDA-MB-468, MDA-MB-321, ZR75.1) or RPMI 1640 (BT474, SkBr3) with 10% FBS and antibiotics (50 IU/mL penicillin, 50 μg/mL streptomycin). MCF10A were maintained in DMEM supplemented with 5% horse serum (Gibco), 0.5 μg/mL insulin (Sigma), 10 ng/mL EGF (Peprotech), 100 ng/mL cholera toxin (List Biochemical Laboratories Inc.), 0.5 μg/mL hydrocortisone (Sigma) and antibiotics. During experiments, MCF10A cells were grown in the absence of insulin. Cell lines were

of PI3K/AKT, and (iv) transcriptional upregulation of eIF4E (15–17). The latter suggests that even complete TORC1 inhibition cannot prevent eIF4E-driven breast tumorigenesis, so targeting eIF4E directly may potentially be a more successful therapeutic strategy. Toward this end, novel approaches including antisense and RNAi-mediated downregulation of eIF4E have shown promising preclinical activity in different cancer models and are now under clinical development (18–20).

We have recently shown that ribavirin, an antiviral drug, inhibits eIF4E and has antitumor activity in tumor cells characterized by elevated levels of eIF4E (21, 22) and in patients with specific subtypes of acute myeloid leukemia (AML; ref. 23). Ribavirin binds to eIF4E, thereby inhibiting its association with the mG-cap and blocking translation and/or mRNA export of specific, eIF4E-dependent transcripts without affecting translation or export of housekeeping mRNAs (21, 22). In particular, the antitumor activity of ribavirin has been associated with decreased protein levels of several eIF4E targets, including cyclin D1, NBS1, and active (phosphorylated) Akt (21, 22). Ribavirin appears to specifically inhibit the proliferation of tumor cells overexpressing eIF4E (22), and this selectivity probably underlies the lack of toxicity observed in our recent clinical trial of ribavirin monotherapy in patients with poor prognosis, eIF4E overexpressing AML. In this study population, ribavirin triggered dramatic clinical improvements, which correlated with relocalization of eIF4E from the nucleus to the cytoplasm, as well as a decrease in total eIF4E levels (23). Direct evidence of decreased mRNA export of the eIF4E-target NBS1, together with reduced protein levels of cyclin D1 and NBS1 were also shown, as was repression of Akt activity.

...
obtained from the American Type Culture Collection prior to 2005, and have not been authenticated since. All culture media, FBS and antibiotics were purchased from Wisent. Lyophilized ribavirin (Kemprotex Ltd.) was dissolved in H₂O at a stock concentration of 50 mmol/L and sterile filtered. Aliquots were kept at –80°C and thawed only once. Normal breast cells were obtained after ethical approval, with informed consent, from patients undergoing prophylactic mastectomy, and were cultured in MEGM (Clonetics).

**Sulphorhodamine B assay**

Cells were seeded in 96-well plates and cultured in the absence or presence of ribavirin. The media was changed and the cells retreated on day 3 and 5. Cell number was assessed as described (29).

**Clonogenic assay**

Cells were seeded at low density in 6-well plates and kept in the presence or absence of ribavirin for 14 days, with the media changed and the cells retreated every 3 days. Cells were then fixed in 10% TCA and stained with sulphorhodamine B (SRB), as above. All visible colonies were manually counted.

**Western blotting**

Whole cell extracts were prepared by lysis of cells in protein lysis buffer (1% Triton X-100, 150 mmol/L NaCl and 50 mmol/L Tris-HCl, pH 8.0) supplemented with protease and phosphatase inhibitors. Twenty to 50 µg of protein were used for Western blotting to detect total eIF4E (BD Biosciences), phospho-4E-BP1 (Thr37/46), total 4E-BP1, phospho-Akt (Ser473) total Akt and NBS1 (all from Cell Signaling), as well as cyclin D1 and VEGF (Santa Cruz). An antibody to β-actin (Sigma) was used to confirm equal protein loading.

**RNA interference**

Cells were transfected with siRNAs at a final concentration of 16 nmol/L using Lipofectamine RNAiMax (Invitrogen) following the manufacturer’s instructions for reverse transfection. Transfections were carried out in 6-well plates for assessment of knockdown by Western blot and in 96-well plates for assessment of cell proliferation by SRB assay. The sequences of the eIF4E siRNA pair were as follows: 5'-AGA GUG GAC UGC AUU UAA AUU UGdA dT-3' and 5'-AUC AAA UUU AAA UGC AGU CCA CUC UGC-3'. As nonsilencing control, we used AllStars Negative Control siRNA (Qiagen).

**Confocal immunofluorescence**

Exponentially growing cells were fixed with methanol, permeabilized with 0.5% Triton-X 100 (in PBS), then blocked with 10% FBS (in PBS). An eIF4E-FITC antibody (BD Biosciences) was used to show the cellular distribution of eIF4E, and the VECTASHIELD Mounting Medium with DAPI was used to visualize the nuclei. Micrographs were collected on a laser scanning confocal microscope (LSM510 Carl Zeiss, Inc.) using a 100× objective with a numerical aperture of 1.4, with further 2 times digital zoom at room temperature.

**Cell fractionation and quantitative PCR**

Cellular fractionation was carried out as previously described (30). Relative quantification of transcripts was carried out using the StepOnePlus Real-Time PCR System with SYBR Green–based detection (Applied Biosystems) using primers described in Supplementary Table S1. All calculations were done using the relative standard curve method described in Applied Biosystems User Bulletin 2. To confirm purity of the fractions, levels of rRNAβ (cytoplasmic) and U6 snRNA (nuclear) were assessed by PCR, as described previously (5).

**Immunoprecipitation**

Cells were incubated with 0.5 µmol/L ³H-ribavirin over night, fixed with 1.2% formaldehyde (15 minutes at room temperature), followed by 0.15 mol/L glycine for 5 minutes. After 2 washes in PBS, cells were lysed in immunoprecipitation (IP) buffer (50 mmol/L Tris pH 7.5, 5 mmol/L EDTA, 150 mmol/L NaCl, 5 mmol/L MgCl₂, 0.5% NP40) followed by sonication. Lysates were precleared with protein G- sepharose (30 minutes at 4°C) and IP was carried out overnight with anti-eIF4E or IgG conjugated agarose beads (Santa Cruz). Beads were washed 6 times with IP buffer and resuspended in 2× SDS elution buffer (15 minutes at 98°C). Eluted proteins were subjected to scintillation counting and Western blot.

**Patient sample collection and immunohistochemistry**

Three-millimeter punch skin biopsies from normal skin tissue and skin metastases were obtained after approval by an institutional review board and with informed consent from patients with breast cancer that had progressed on prior anthracycline and taxane-containing regimens. Biopsies were sectioned, stained with anti-eIF4E antibody (BD Bioscience) and analyzed by a board certified pathologist as part of the Histology Platform service at the Institute for Research in Immunology and Cancer (IRIC), Université de Montréal.

**Analysis of breast cancer microarray data**

Expression data from 4 independent studies (GSE3521, GSE15852, GSE18672 and GSE10780) were obtained from the Gene Expression Omnibus (GEO) to assess whether eIF4E mRNA is elevated in primary breast cancers and metastatic lesions over normal breast epithelium. eIF4E gene expression levels within each tissue type were visualized using box plots and compared using t test. In addition, to assess the prognostic value of eIF4E mRNA expression, 683 adjuvant untreated, node negative breast cancer cases annotated for DMFS were pooled from 4 sources [GSE2034, GSE5327, GSE7390, NKI295 (31)]. Each sample was assigned to 1 of 5 subtypes: luminal A (LumA), luminal B (LumB), HER2, basal, or normal-like (normal). Survival analysis was restricted to a subset of 621 patients.
cases with 15 or less year follow-up to avoid curve instability at extremely long follow-up times. Tumors were dichotomized based on median eIF4E mRNA level and association with DMFS was assessed by Kaplan–Meier analysis in all 621 cases, as well as within each intrinsic breast cancer subtype. For comparison, the prognostic value of mTOR or the ratio of eIF4E with its binding proteins (4EBP1, 4EBP2, and PML) mRNA expression levels was similarly assessed. As well, eIF4E expression levels within each intrinsic subtype were represented by box plots and compared by t test. Details on expression data processing and subtype assignment, as well as relevant references for individual GEO datasets, are described in Supplemental Methods S1.

Results

Ribavirin suppresses proliferation and clonogenic potential of breast cancer cell lines

In patients with AML receiving ribavirin therapy, plasma levels of up to 88 μmol/L have been measured (unpublished data). We treated 6 breast cancer cell lines, plus the nontumorigenic mammary epithelial cell line MCF10A (32), with up to 100 μmol/L ribavirin and assessed effects on cell proliferation and clonogenic potential. Seven days of ribavirin treatment revealed that all cell lines tested were growth inhibited with IC50 values that are within the clinically achievable range (Fig. 1A). Two cell lines were less sensitive than the others, namely, MCF10A and ZR75.1. Additionally, assessment of the growth inhibitory activity of ribavirin in normal primary breast cells (n = 3) showed no response at concentrations up to 120 μmol/L.

Assessment of anchorage-dependent clonogenic potential in the absence or presence of ribavirin showed significant inhibition at concentration ranging from 1 to 50 μmol/L (Fig. 1B). Between 20 and 100 μmol/L ribavirin was required to completely suppress the ability of the tumor cell lines to form colonies, whereas MCF10A cells were 50% inhibited at 100 μmol/L. We note that ZR75.1 cells were less sensitive to ribavirin than all other cell lines with comparably elevated eIF4E.

Ribavirin growth inhibition is associated with downregulation of known eIF4E targets and is suppressed by knockdown of eIF4E

We used several strategies to confirm that ribavirin targets eIF4E in breast cancer cells. Because the antitumor effects of ribavirin have been associated with decreased mRNA export as well as translation of eIF4E sensitive transcripts (22), we first assessed changes in the levels of nuclear and cytoplasmic mRNA of known eIF4E targets. As expected, we observed a reduced ratio of cytoplasmic to nuclear NBS1, ODC, and cyclin D1 mRNA in cells treated with ribavirin for 72 hours, indicating inhibition of nuclear mRNA export (Fig. 2A). In contrast, the ratio of cytoplasmic to nuclear TBP mRNA was unaffected by ribavirin, consistent with it not being an eIF4E target (Fig. 2A). Total mRNA levels of cyclin D1 or NBS1 were not affected by ribavirin treatment (Fig. 2B), but a reduction in the protein levels of these eIF4E targets was evident (Fig. 2C).

Earlier studies in NIH3T3 cells indicated that ribavirin treatment led to reduction in polysomal loading of VEGF with no alteration in mRNA export (22) and, consistent with this, we observed a decrease in the protein level of VEGF.
These data indicate that ribavirin modulates both the nuclear and the cytoplasmic function of eIF4E in breast cancer cells, in accordance with data from other cell types. Ribavirin has previously been shown to suppress the activity of AKT, via a reduction in NBS1 (21, 33). Consistently, we observed a decrease in active, phosphorylated AKT (Fig. 2D). We also assessed phosphorylation of 4EBP1, which is a target of mTOR downstream of AKT and observed a dose-dependent reduction in the hyperphosphorylated form of this protein (Fig. 2D), confirming suppression of AKT signaling. To show that ribavirin binds eIF4E in these cells, we treated cells with 3H-labeled ribavirin for 24 hours, and carried out IP of eIF4E followed by scintillation counting. These studies showed a 4-fold increase in 3H-ribavirin coimmunoprecipitated with eIF4E, relative to the IgG control (Fig. 2E). Finally, we used siRNA to knock down eIF4E in BT474 cells, which are highly responsive to ribavirin, and assessed the effect on cell growth inhibition.
proliferation in the absence or presence of the drug. As expected, knockdown of eIF4E caused a robust decrease in cell proliferation; moreover, there was little additional suppression of proliferation by ribavirin (Fig. 2F).

**eIF4E is highly expressed in the cytoplasm and nucleus of all breast cancer cell lines**

eIF4E mRNA and protein levels in exponentially growing cells were assessed by Western blot, which showed elevated levels in all tumor cell lines. Immunofluorescence staining of eIF4E (green) in BT474, MDA-MB-468, MDA-MB-231, and ZR75.1 cells shows that eIF4E is present in the nucleus as well as the cytoplasm.

Metastatic breast cancers show concordant overexpression of eIF4E mRNA and protein

To investigate whether eIF4E mRNA is elevated in patient tumors, and whether metastatic lesions also display high eIF4E expression, we first examined microarray data from 3 publicly available datasets (GSE15852, GSE18672 and GSE10780), and found that in each of the datasets, average eIF4E mRNA levels were significantly higher in primary breast tumors than in normal breast (Fig. 4A). Further, analysis of 1 dataset (GSE3521), containing samples from primary breast cancers as well as metastases and normal breast, showed significantly elevated levels in both primary tumors and metastases (Fig. 4B). We also obtained biopsy material from 3 patients with advanced breast cancer that had metastasized to the skin. All patients had undergone chemotherapy and were experiencing progressive disease at the time of biopsy. qPCR analysis showed 2.5 to 3.5-fold increased levels of eIF4E mRNA compared to normal skin (Fig. 4C), although this is likely to be an underestimate due to contamination of the tumor biopsies with normal cells. Immunohistochemistry (IHC) also showed strong positive staining for eIF4E in malignant skin, whereas normal skin showed much weaker staining, with the exception of the epidermis (Fig. 4D), indicating a concordant increase in eIF4E expression at the mRNA and protein level.

High eIF4E mRNA expression is a prognostic factor in patients with luminal B breast cancer

To determine the prognostic value of eIF4E mRNA, we analyzed pooled microarray data from 621 adjuvant untreated, node negative breast cancers for eIF4E expression levels and correlation with DMFS. Tumors were dichotomized into High versus Low expressors at the median, and Kaplan–Meier analysis revealed that high eIF4E expressing breast cancers have reduced DMFS when compared to low eIF4E expressors (Fig. 5A). In comparison, mTOR mRNA expression did not produce significant curve separation between High versus Low expressing groups (Fig. 5B). eIF4E availability/activity is regulated by many proteins, including 4EBPs, PML, and others; thus we also examined the prognostic value of the ratios of eIF4E/BP1, eIF4E/4EBP2, and eIF4E/PML mRNA. Neither eIF4E/4EBP2 nor eIF4E/PML mRNA expression produced significant curve separation between High versus Low expressing groups (Fig. 5C and D). Interestingly, high eIF4E/4EBP1 ratio appears to be associated with better prognosis (Fig. 5E), although this is likely due to low 4EBP1 expression (and hence high eIF4E/4EBP1 ratios) in the good prognosis luminal A subtype (Supplementary Fig. S2). When the cohort was subset into intrinsic breast cancer subtypes, comparison of eIF4E mRNA expression levels revealed that luminal B breast cancers have the highest average eIF4E mRNA levels (Fig. 6A). These differences are significant for comparisons with basal, luminal A, and normal-like cases (t test, \( P = 1.03E-04, 2.17E-03, \) data not shown), which is typical of most cell lines and primary tissues (36).
4.85E-07, respectively), but not with the HER2 subtype (t-test, P = 0.29). When the prognostic value of eIF4E was assessed within each intrinsic subtype, significant discrimination between good and poor outcome groups was observed in luminal B cases (Fig. 6B), and not in any of the other subtypes (Fig. 6C–F), suggesting that the overall prognostic significance of eIF4E in the pooled dataset may be attributed mainly to its discriminating power in the luminal B subset of breast cancer cases. Interestingly, the prognostic value of the ratio of eIF4E/4E-BP2 and eIF4E/PML show the same intrinsic subtype specificity, where significant curve separations were observed only in luminal B cases (Supplementary Figs. S3 and S4). In contrast, mTOR and the eIF4E/4EBP1 mRNA ratios did not show prognostic significance in any individual intrinsic subtypes (data not shown).

Discussion

Overexpression of eIF4E, an oncogene that posttranscriptionally regulates the expression of many genes critical to cell division, proliferation, and angiogenesis, is associated with oncogenic transformation in cell culture and with tumor formation, metastatic disease, and increased tumor invasion in mice (37, 38). From a number of small to medium size studies in breast cancer, it has been reported that overexpression of eIF4E at the protein level is a common event, which correlates with aggressive disease and poorer patient prognosis (2–4, 39). In agreement with these reports, we found that eIF4E mRNA is elevated in primary as well as metastatic breast cancer relative to normal breast tissue. * denotes significance by t test (P < 0.05). C, mRNA levels in malignant and normal skin were assessed by qPCR and results were normalized to RPL13a. For each patient, normal skin was used as a calibrator (RQ = 1). D, IHC shows strong eIF4E staining in malignant skin.
This study is the first to show that clinically relevant concentrations of ribavirin, a confirmed inhibitor of eIF4E (22), suppress proliferation, and clonogenecity of a number of breast cancer cell lines (Fig. 1). All breast cancer cell lines tested express levels of eIF4E that are substantially higher than that of the nonmalignant mammary cell line MCF10A (Fig. 3), and all are sensitive to ribavirin within the therapeutic range. In cell proliferation assays, IC50 values varied from 7 to 50 μmol/L ribavirin; and all cells with elevated eIF4E levels were also sensitive to high levels of ribavirin in colony forming assays with no colonies formed at 100 μmol/L ribavirin, in contrast to the non-malignant MCF10A line where colonies formed even in the presence of this high ribavirin concentration. These results suggest that within the therapeutic concentration range evaluated, all breast cancer cells are responsive to ribavirin, with their observed variation in ribavirin sensitivity likely caused by individual genetic and/or epigenetic features that potentially impact the eIF4E pathway. For instance, not only the expression level but also the activity of eIF4E is a critical determinant of cell growth, and its activity regulation is known to be redundant and multi-factorial (8, 9, 44, 45). Variations in the levels of positive and negative eIF4E regulatory proteins, including 4EBPs, 4E-T, maskin, CUP, PML, and others, as well as the activity of the AKT/mTOR pathway or the eIF4E kinase Mnk, may modulate the effectiveness of ribavirin.

As expected, growth inhibition by ribavirin was accompanied by decreased cytoplasmic to nuclear mRNA ratios and protein levels of known eIF4E export targets, as well as the cytoplasmic target VEGF (Fig. 2A–C). We also showed for the first time that siRNA mediated knockdown of eIF4E protein in BT474 cells prevents further antiproliferative activity of ribavirin, supporting the essential role of eIF4E in mediating ribavirin’s antitumor activity. Given these data, we conclude that eIF4E overexpression is essential for ribavirin responsiveness, and that additional influences may modulate ribavirin sensitivity.

Importantly, and consistent with previous studies in the head and neck squamous cell carcinoma (HNSCC) cell line FaDu (21), in fibroblasts and in AML patients undergoing ribavirin treatment, we observed that suppression of cell growth by ribavirin was associated with a decrease in AKT signaling, as shown by decreased phospho-AKT and phospho-BP1 (Fig. 2D). This suppression works as a negative feedback toward eIF4E activity, by allowing hypo-phosphorylated BP1 to sequester eIF4E, and thus provides a double antiproliferative signal in tumor cells that in addition to overexpressing eIF4E may have mutations activating the PI3K/AKT/mTOR pathway. Of note, basal-like breast cancers are associated with frequent PTEN loss and PI3K activation (46, 47) and the sensitivity of MDA-MB-468, a basal cell line that lacks PTEN and has constitutively activated PI3K/AKT signaling, to ribavirin induced growth inhibition implicates potential therapeutic value in this clinically problematic subset of breast cancers. The ability of ribavirin to suppress AKT clearly distinguishes it from clinically available mTOR inhibitors, which have the...
opposite effect, and suggests that it may indeed be more beneficial to directly target eIF4E, which acts both upstream and downstream of PI3K/AKT/mTOR.

Complementary to the evaluation of eIF4E as a therapeutic target in breast cancer cells, we have carried out the first large survey assessing the prognostic value of total eIF4E mRNA expression in a cohort of over 600 node negative adjuvant naive breast cancers, sufficiently powered to evaluate expression levels within specific intrinsic subtypes in relation to metastatic recurrence. Surprisingly, despite previous links between elevated eIF4E protein expression and poor breast cancer prognosis (2–4, 39), the reduction in DMFS observed in breast cancers with elevated eIF4E mRNA levels were only barely significant ($P = 0.05$; Fig. 5A). This disparity may in part be accounted for by the high degree of heterogeneity among breast cancers and, indeed, when each intrinsic subtype was analyzed separately, high eIF4E mRNA was correlated with poor prognosis specifically in luminal B breast cancers, and this correlation was highly significant. This prognostic association suggests that eIF4E overexpression in luminal B breast cancers not only contributes to their greater clinical aggressiveness and endocrine resistance relative to luminal A breast cancers, but it also points to a possible mechanistic difference in the tumorigenic pathways driving these 2 types of ER-positive breast cancer. Luminal B breast cancers are potentially more dependent on the downstream translational products induced by overexpressed eIF4E and therefore more susceptible to eIF4E-targeted therapeutics. Of note, high eIF4E/BP2 and eIF4E/PML ratios were also associated with poor prognosis in the luminal B cancers; however, eIF4E alone gives the best prognostic performance. This is in contrast to observations at the protein level where parameters which include 4EBP levels improve prognostic performance over eIF4E levels alone (48). Among the breast cancer cell lines we tested for ribavirin responsiveness one of the most sensitive lines was BT474, which is ER-positive and HER2 amplified and potentially considered to be luminal B (34). It is difficult to assign cell lines to intrinsic subtypes, as the subtyping of cell lines by Neve and colleagues did not distinguish between luminal A and luminal B categories (34), but HER2 amplification along with ER and/or PR positivity is commonly employed as an immunohistochemical surrogate.
of the luminal B subtype (49). However, we note that other sensitive cell lines, such as MDA-MB-468, are of the basal-like subtype (34). It is important to concede that a prognostic marker may not be predictive of response, even to a drug targeting the marker.

Our findings provide strong rationale for the ongoing phase I/II clinical study evaluating ribavirin in the setting of advanced breast cancer (NCT01056757), and correlative studies linked to this trial will help determine if luminal B and possibly some basal-like breast cancers are more sensitive to eIF4E-targeted therapy. Since eIF4E-targeted agents will most likely find their greatest clinical utility in combination with standard breast cancer therapeutics, additional preclinical studies must now begin to determine what specific classes of chemotherapeutics or endocrine agents are best given in combination with eIF4E-targeted therapeutics. We foresee that analogs of ribavirin with improved eIF4E targeting and pharmacologic properties will be developed in the coming years and that this new class of targeted agents will not only become useful in the management of breast cancer patients, but they will also become part of an emerging group of breast cancer subtype-selective therapeutics.

Disclosure of Potential Conflicts of Interest

No potential conflicts of interest were disclosed.

Acknowledgments

The authors thank Dr. Louis Gaboury and the histology platform at IRIC for IHC staining of eIF4E in skin biopsies.

Grant Support

This research was supported in part by a BCRF-AACR Grant for Translational Breast Cancer Research (W.H. Miller). Other financial support was received from the Canadian Institute for Health Research (CIHR MOP-12863, W.H. Miller and F. Pettersson, MOP-43979, W.H. Miller), National Cancer Institute of Canada (NCIC #19202, W.H. Miller), NIH-P50CA58207, R01-AG032113, and U24-CA14358 (C.C. Benz and C. Yau), and NIH-89571 (K.L.B. Borden). W.H. Miller is a Chercheur National de Fonds de la Recherche en Santé du Québec (FRSQ) and K.L.B. Borden holds a Canada Research Chair.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Received August 31, 2010; revised February 8, 2011; accepted February 9, 2011; published OnlineFirst March 17, 2011.


Correction: Ribavirin Treatment Effects on Breast Cancers Overexpressing eIF4E, a Biomarker with Prognostic Specificity for Luminal B-Type Breast Cancer

In this article (Clin Cancer Res 2011;17:2874–84), which was published in the May 1, 2011, issue of Clinical Cancer Research (1), the name of the fifth author is misspelled. The correct spelling is Hélène Retrouvey.

Reference

Published OnlineFirst October 18, 2011. ©2011 American Association for Cancer Research. doi: 10.1158/1078-0432.CCR-11-2278
Ribavirin Treatment Effects on Breast Cancers Overexpressing eIF4E, a Biomarker with Prognostic Specificity for Luminal B-Type Breast Cancer

Filippa Pettersson, Christina Yau, Monica C. Dobocan, et al.

Clin Cancer Res 2011;17:2874-2884. Published OnlineFirst March 17, 2011.

Updated version
Access the most recent version of this article at: doi:10.1158/1078-0432.CCR-10-2334

Supplementary Material
Access the most recent supplemental material at: http://clincancerres.aacrjournals.org/content/suppl/2011/05/05/1078-0432.CCR-10-2334.DC1

Cited articles
This article cites 49 articles, 22 of which you can access for free at: http://clincancerres.aacrjournals.org/content/17/9/2874.full.html#ref-list-1

Citing articles
This article has been cited by 9 HighWire-hosted articles. Access the articles at: http://clincancerres.aacrjournals.org/content/17/9/2874.full.html#related-urls

E-mail alerts
Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions
To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions
To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org.